Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hormonal replacement therapy and the skeletal system.

C Christiansen1, B J Riis

  • 1Department of Clinical Chemistry, Glostrup Hospital, Denmark.

Maturitas
|September 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial.

Bone·2018
Same author

Cohort Profile: The Prospective Epidemiological Risk Factor (PERF) study.

International journal of epidemiology·2016
Same author

Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials.

Osteoarthritis and cartilage·2015
Same author

OA phenotypes, rather than disease stage, drive structural progression--identification of structural progressors from 2 phase III randomized clinical studies with symptomatic knee OA.

Osteoarthritis and cartilage·2015
Same author

Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis.

Bone·2012
Same author

Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2011

Identifying women at risk for osteoporosis involves assessing peak bone mass and postmenopausal bone loss. Early detection allows for preventive therapies like hormone replacement therapy (HRT) to reduce fracture risk.

Area of Science:

  • Bone biology and skeletal health.

Background:

  • Maintaining skeletal health depends on peak bone mass and bone loss rates.
  • Osteoporosis risk is elevated in women with low peak bone mass and rapid bone loss.

Purpose of the Study:

  • To identify women at high risk for osteoporosis.
  • To evaluate methods for assessing bone mass and postmenopausal bone loss.

Main Methods:

  • Bone mass assessment using single photon absorptiometry in the forearm.
  • Estimation of postmenopausal bone loss via biochemical markers of bone turnover.

Main Results:

  • Hormone replacement therapy (HRT) effectively halts bone loss in postmenopausal women.
  • Epidemiological studies confirm HRT reduces osteoporotic fractures.

Related Experiment Videos

Conclusions:

  • Combining bone mass measurement with bone loss markers aids in identifying at-risk women.
  • Preventive therapy, such as HRT, is recommended for high-risk individuals to mitigate osteoporosis and fractures.